1.Sales and profit
See section β- Octave Specialty Group Inc had $251M of revenue in fiscal 2025, up 6.5% on the year before. Over five years, revenue changed +10.0% a year on average.
- Octave Specialty Group Inc lost $259M in fiscal 2025.
OSG NYSE Surety Insurance Financials FY2016βFY2025
Octave Specialty Group Inc had $251M of revenue in fiscal 2025, up 6.5% on the year before. Over five years, revenue changed +10.0% a year on average.
Last close Β· Oct 23, 2026
$4.75
0.6%Hi! I read Octave Specialty Group Incβs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+6.5%
Yes. Sales grew 6.5% last year.
Does it make a profit?
β103.1%
No. It lost money last year.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
KIRA Β· Octave Specialty Group Inc had $251M of revenue in fiscal 2025, up 6.5% on the year before. Over five years, revenue changed +10.0% a year on average.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Octave Specialty Group Inc lost $259M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
KIRA Β· Octave Specialty Group Inc returned $29.9M to shareholders in fiscal 2025. The diluted share count rose 0.5%.
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· In the last 12 months, insiders bought $0.1M of shares on the open market and sold none.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.1M
2 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jan 2, 2026 | Claude LeBlancChief Executive Officer, Director | Bought | 12,000 | $7.59 | $0.1M | Form 4 |
| Nov 12, 2025 | R Sharon SmithExec VP & Group COO | Bought | 20 | $10.25 | $0.0M | Form 4 |
| Oct 1, 2025 | Claude LeBlancChief Executive Officer, Director | Bought | 25,000 | $8.54 | $0.2M | Form 4 |
Can it carry its debts, and how well does it use its money?
KIRA Β· Octave Specialty Group Inc has $97.3M more cash than debt.
Cash, debt and the ratios that show how comfortably Octave Specialty Group Inc can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $431M | $513M | $208M | $157M | $215M |
| Debt incl. finance leases | $2.2B | $639M | $508M | $150M | $118M |
| Debt / equity | 2.1x | 0.5x | 0.4x | 0.2x | 0.2x |
| Total assets | $12.3B | $8.0B | $8.4B | $8.1B | $2.2B |
| Total liabilities | $11.2B | $6.6B | $7.0B | $6.9B | $1.1B |
| Shareholders' equity | $1.0B | $1.3B | $1.4B | $798M | $716M |
| Net debt (β = net cash) | $1.8B | $126M | $300M | β$7.2M | β$97.3M |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Octave Specialty Group Inc passes 2 of 7 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 4 / 7 | 2 / 7 | 2 / 7 | 3 / 7 | 6 / 7 | 6 / 7 | 4 / 7 | 2 / 7 |
| Accruals ratio | β0.5% | 9.2% | 0.7% | β2.0% | 0.9% | β8.0% | β2.4% | β6.8% | β4.0% |
| Altman Z'' | β | β | β | β | β | β | β | β | β |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | β | $622M | $511M | $496M | $156M | $282M | $53.6M | $125M | $236M | $251M |
| Interest expense | β | $120M | $242M | $269M | $222M | $187M | $0.0M | $0.0M | $9.4M | $18.6M |
| Pretax income | β | β$284M | $273M | β$183M | β$440M | $2.0M | β$35.7M | β$24.2M | β$59.8M | β$101M |
| Income tax | β | $44.0M | $5.0M | $32.0M | β$3.0M | $18.0M | β$0.5M | $1.0M | $0.9M | $5.2M |
| Net income | β | β$329M | $186M | β$216M | β$437M | β$17.0M | $522M | $5.0M | β$556M | β$259M |
| Net income to common | β | β | β | β$216M | β$437M | β$28.0M | $522M | $3.6M | β$556M | β$262M |
| Diluted EPS | β | β$7.25 | $3.99 | β$4.69 | β$9.47 | β$0.61 | $11.48 | $0.18 | β$11.96 | β$5.93 |
| Diluted shares | β | 0.05B | 0.05B | 0.05B | 0.05B | 0.05B | 0.05B | 0.05B | 0.05B | 0.05B |
| Cash flow | ||||||||||
| Cash from operations | β | β$221M | β$1.5B | β$311M | β$175M | β$131M | $1.3B | $200M | $0.8M | β$52.3M |
| Depreciation and amortization | β | $1.0M | $1.0M | $0.0M | $1.0M | $2.0M | $0.9M | $5.2M | $19.9M | $42.0M |
| Stock-based compensation | β | $4.0M | $12.0M | $12.0M | $11.0M | $14.0M | $11.2M | $12.3M | $9.4M | $9.7M |
| Acquisitions | β | β | β | β | β$74.0M | $0.0M | $18.4M | $7.0M | $244M | $218M |
| Share buybacks | β | β | β | β | β | β | $14.2M | $4.5M | $11.7M | $29.9M |
| Dividends and buybacks | β | β | β | β | β | β | $14.2M | $4.5M | $11.7M | $29.9M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $91.0M | $624M | $63.0M | $24.0M | $512M | $431M | $513M | $208M | $157M | $215M |
| Total debt | β | $992M | $2.9B | $2.8B | $2.7B | $2.2B | $639M | $508M | $150M | $118M |
| Goodwill | β | β | β | β | $46.0M | $46.0M | $46.1M | $69.7M | $418M | $540M |
| Intangible assets | β | $847M | $719M | $427M | $409M | $362M | $326M | $61.4M | $345M | $475M |
| Total assets | β | $23.2B | $14.6B | $13.3B | $13.2B | $12.3B | $8.0B | $8.4B | $8.1B | $2.2B |
| Total liabilities | β | $21.5B | $13.0B | $11.8B | $12.1B | $11.2B | $6.6B | $7.0B | $6.9B | $1.1B |
| Preferred stock | β | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $2.0B | $1.4B | $1.6B | $1.5B | $1.1B | $1.0B | $1.3B | $1.4B | $798M | $716M |
| Margins | ||||||||||
| Net margin | β | β52.9% | 36.4% | β43.5% | β280.1% | β6.0% | 973.9% | 4.0% | β235.8% | β103.1% |
| Returns | ||||||||||
| Return on equity | β | β19.6% | 12.5% | β14.1% | β34.2% | β1.6% | 45.6% | 0.4% | β51.5% | β34.2% |
| Return on assets | β | β1.4% | 1.0% | β1.5% | β3.3% | β0.1% | 5.2% | 0.1% | β6.7% | β5.0% |
| Return on tangible equity | β | β61.6% | 21.3% | β20.6% | β69.9% | β4.4% | 59.4% | 0.3% | β1,573.9% | β |
| Growth | ||||||||||
| Revenue growth | β | β | β17.8% | β2.9% | β68.5% | 80.8% | β81.0% | 132.6% | 89.1% | 6.5% |
| Net income growth | β | β | β | β216.1% | β | β | β | β99.1% | β11,331.8% | β |
| EPS growth | β | β | β | β217.5% | β | β | β | β98.4% | β6,744.4% | β |
| Share count change | β | β | 0.0% | β1.3% | 0.4% | 0.8% | β1.8% | β0.2% | 2.9% | 0.5% |
| Financial health | ||||||||||
| Debt / equity | β | 0.7x | 1.8x | 1.9x | 2.5x | 2.1x | 0.5x | 0.4x | 0.2x | 0.2x |
| Capital allocation | ||||||||||
| Stock comp / revenue | β | 0.6% | 2.3% | 2.4% | 7.1% | 5.0% | 20.9% | 9.8% | 4.0% | 3.9% |
| Quality scores | ||||||||||
| Piotroski F-score | β | β | 4.0 | 2.0 | 2.0 | 3.0 | 6.0 | 6.0 | 4.0 | 2.0 |
| Accruals ratio | β | β0.5% | 9.2% | 0.7% | β2.0% | 0.9% | β8.0% | β2.4% | β6.8% | β4.0% |
Source: SEC EDGAR XBRL filings (CIK 0000874501). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.